Robert Weisskoff

Robert is a partner at F-Prime Capital where he has invested in multiple companies with successful exits including Accuri Cytometers (acquired by Becton Dickinson), Ikano Therapeutics (acquired by UCB), and Topaz (acquired by Sanofi Pasteur). Prior to F-Prime, he worked extensively in both academia and in industry. In industry, Robert held senior roles in R&D and business development at pharmaceutical and medical device companies. He is the author of more than 100 scientific papers and an inventor on six patents. Robert serves on the Board of multiple portfolio companies including Farapulse, Tempest Therapeutics, and Xilio Therapeutics. He received his B.A. degree in Physics from Harvard University, Ph.D. in Physics from the Massachusetts Institute of Technology and M.B.A. from Columbia University.